Asset Management One
RPRX icon

Asset Management One’s Royalty Pharma RPRX Stock Holding History

Asset Management One’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8M Buy
334,878
+64,352
+24% +$3.35M 0.05% 316
2026
Q1 		$13M Buy
270,526
+79,617
+42% +$3.49M 0.04% 383
2025
Q4 		$7.46M Sell
190,909
-17,023
-8% -$649K 0.02% 538
2025
Q3 		$7.34M Sell
207,932
-22,499
-10% -$815K 0.02% 537
2025
Q2 		$8.3M Buy
230,431
+65,500
+40% +$2.17M 0.03% 488
2025
Q1 		$5.13M Buy
164,931
+12,148
+8% +$385K 0.02% 601
2024
Q4 		$3.9M Buy
152,783
+4,427
+3% +$117K 0.01% 658
2024
Q3 		$4.2M Buy
148,356
+5,942
+4% +$165K 0.01% 639
2024
Q2 		$3.76M Sell
142,414
-4,797
-3% -$133K 0.01% 640
2024
Q1 		$4.47M Sell
147,211
-1,143
-0.8% -$33.7K 0.02% 617
2023
Q4 		$4.15M Sell
148,354
-14,664
-9% -$403K 0.02% 639
2023
Q3 		$4.42M Sell
163,018
-479
-0.3% -$14.2K 0.02% 608
2023
Q2 		$5.03M Sell
163,497
-8,311
-5% -$281K 0.02% 584
2023
Q1 		$6.19M Buy
171,808
+37,997
+28% +$1.41M 0.03% 519
2022
Q4 		$5.29M Sell
133,811
-4,859
-4% -$203K 0.03% 547
2022
Q3 		$5.57M Buy
138,670
+5,628
+4% +$240K 0.03% 513
2022
Q2 		$5.59M Sell
133,042
-3,099
-2% -$127K 0.03% 551
2022
Q1 		$5.3M Sell
136,141
-7,220
-5% -$284K 0.02% 618
2021
Q4 		$5.73M Buy
143,361
+70,408
+97% +$2.74M 0.02% 627
2021
Q3 		$2.64M Sell
72,953
-4,798
-6% -$186K 0.01% 784
2021
Q2 		$3.19M Sell
77,751
-2,935
-4% -$125K 0.01% 772
2021
Q1 		$3.52M Buy
80,686
+25,067
+45% +$1.19M 0.01% 733
2020
Q4 		$2.76M Buy
+55,619
New +$2.36M 0.01% 755

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Asset Management One's RPRX Position: Q2 2026 in Review

Asset Management One increased its Royalty Pharma (RPRX) stake by 24% in Q2 2026, buying an estimated $3.35M and bringing the position to 334,878 shares worth $18.8M. The position accounts for 0.05% of the portfolio, ranked #316.

Asset Management One first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Asset Management One held 334,878 shares of Royalty Pharma worth $18.8M as of Q2 2026.
  • Asset Management One bought 64,352 Royalty Pharma shares in Q2 2026, an estimated $3.35M.
  • Royalty Pharma made up 0.05% of Asset Management One's portfolio in Q2 2026, its #316 holding.
  • Asset Management One first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Asset Management One's 13F filing for Q2 2026, filed 28 Jul 2026.